Skip to main content
. 2015 Jun 30;64(10):3564–3572. doi: 10.2337/db15-0022

Figure 4.

Figure 4

Diabetes study. A: SGLT1 shRNA AAV microinjection reduced VMH SGLT1 mRNA levels ∼57%. B: Plasma glucose concentrations during the clamp in control and SGLT1 knockdown (KD) groups. C: GIRs during the clamp were matched in STZ + SGLT1 KD rats compared with STZ + scrambled AAV rats. D: A significant increase in the epinephrine response to hypoglycemia in STZ-diabetic rats was found. *P < 0.05 vs. STZ + SGLT1 KD; **P < 0.01 vs. STZ + SGLT1 KD.